[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infection-hospital\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infection-hospital":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100475795","impact-of-discontinuing-contact-precautions-for-extended-spectrum--lactamase-enterobacteriaceae-in-a-geriatric-unit-100475795",false,"NCT05475574","Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit","Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae (ESBLE) in a Geriatric Unit: an Interventional Prospective Noninferiority Non-randomized Double-blind Controlled Before and After Study","Ger-SP","Inclusion Criteria:\n\n* Adult patient (\\> 65 years old)\n* Patient hospitalized in geriatrics during the study period\n* Free and informed consent obtained from the patient (or his trusted person or legal representative) within 48 hours of its admission at the geriatric unit\n* Patient affiliated to a social security scheme\n\nNon Inclusion Criteria:\n\n* Patient requiring contact precaution for an indication other than ESBLE (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC) on admission\n* Patient under legal protection\n* Person deprived of liberty\n\nExclusion criteria:\n\n* Patient requiring contact precaution for an indication other than ESBL during the patient stay (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC)\n* Patient's stay period less than 4 days","ALL","65 Years",{"count":20,"type":21},954,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an interventional multicenter prospective noninferiority non-randomized double-blind controlled before and after study.\n\nThe aim of this study is to demonstrate that standard precautions alone are not inferior to contact precautions by comparing the incidence density of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae acquired in geriatric units before and after discontinuing contact precautions.",[27],"Infection, Hospital","RECRUITING","2026-06-20",{"date":31,"type":32},"2026-06-24","ACTUAL",{"date":34,"type":32},"2023-03-07",{"date":36,"type":21},"2029-09-21",{"name":38,"class":39},"Centre Hospitalier Régional Metz-Thionville","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100610919","hydrogen-peroxide-and-ultraviolet-light-for-disinfecting-surfaces-in-intensive-care-units-100610919","NCT07233837","Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units","Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units: A Randomized, Controlled, Cluster, Crossover Clinical Trial","Hylight","Inclusion Criteria:\n\n* All patients aged 18 years and older who will be admitted to the participating ICUs\n\nExclusion Criteria:\n\n* Patients under 18 years\n* ICUs that use peroxide hydrogen or ultraviolet light for surface disinfection as part of their protocol","18 Years",{"count":51,"type":21},5000,[24],"Healthcare-associated infections (HAIs) remain a major problem in intensive care units (ICUs), driven by environmental contamination with multidrug-resistant organisms that persist despite routine manual cleaning. While hydrogen peroxide aerosolization and ultraviolet-C light devices have shown promise in reducing surface contamination, current evidence is inconsistent, mostly derived from single-center studies, and rarely linked to patient-centered outcomes.\n\nThe investigators will conduct this cluster-randomized, crossover trial in 12 Brazilian ICUs. Each ICU will sequentially implement three strategies: (1) usual surface disinfection; (2) usual surface disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration, applied through a dedicated device inside a protective tent during terminal cleaning of patient beds; and (3) usual surface disinfection followed by automated ultraviolet-C irradiation, also applied under the same tent to shield adjacent occupied beds.\n\nThe primary outcome will be the antimicrobial utilization, measured as daily defined doses (DDD) of antimicrobials at the ICU level per 100 patient-days, with secondary outcomes including HAI incidence rate, environmental contamination with multidrug-resistant organisms, specific HAIs incidence rate (associated-ventilator pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection), and ICU length of stay costs.",[27,55,56,57,58],"Antimicrobial","Pneumonia Associated With Mechanical Ventilation","Urinary Tract Infection(UTI)","Catheter Related Blood Stream Infections",[60,61,62,63,64,65,66,67],"Healthcare associated infections","Antimicrobial use","Intensive care units","pneumonia, ventilator-associated","Catheter-related infections","Urinary tract infections","Hydrogen Peroxide","Ultraviolet light","2026-04-10",{"date":70,"type":32},"2026-04-15",{"date":72,"type":32},"2026-01-05",{"date":74,"type":21},"2027-03-01",{"name":76,"class":39},"Hospital Israelita Albert Einstein",12,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":40},"100451068","infectious-complications-after-cystectomy-a-prospective-observational-study-100451068","NCT05153694","Infectious Complications After Cystectomy: A Prospective Observational Study","Inclusion Criteria:\n\n* Disease which requires removal of the urinary bladder\n\nExclusion Criteria:\n\n* Patient does not want to participate",{"count":85,"type":21},200,"OBSERVATIONAL","Patients undergoing cystectomy for either oncological or non-oncological indications are prospectively enrolled following informed consent. This study design incorporates a comprehensive medical history, detailed prospective documentation of clinicopathological parameters, and serial measurements of infectious markers pre- and post-operatively. In-hospital complications are meticulously recorded, and long-term outcomes assessed through structured follow-up interviews at 3, 6, and 12 months. These follow-ups utilize standardized questionnaires to evaluate post-discharge infectious complications and gather patients' perspectives on their in-hospital experiences, providing a robust understanding of both clinical outcomes and patient-reported experiences.",[89,90,91,27,92,93,94,95],"Bladder Cancer","Infections","Infection, Bacterial","Infection Wound","Urinary Tract Infections","Urinary Bladder Diseases","Urinary Tract Disease","2024-09-13",{"date":98,"type":32},"2024-09-19",{"date":100,"type":32},"2021-12-01",{"date":102,"type":21},"2025-12-31",{"name":104,"class":39},"Ludwig-Maximilians - University of Munich"]